ST天圣(002872) - 2021 Q1 - 季度财报

Financial Performance - Revenue for Q1 2021 was CNY 334,030,966.92, representing a 14.37% increase compared to CNY 292,060,015.82 in the same period last year[9] - Net profit attributable to shareholders was a loss of CNY 25,296,030.22, a decrease of 223.42% from a loss of CNY 8,586,532.25 in the previous year[9] - Basic and diluted earnings per share were both CNY -0.0795, a decrease of 223.17% from CNY -0.0270 in the previous year[9] - The net profit for the first quarter was a loss of ¥25,263,753.07, compared to a loss of ¥9,088,220.38 in the same period last year, indicating a deterioration in financial performance[50] - Operating profit showed a loss of ¥24,773,886.05, compared to a loss of ¥8,296,173.68 in the previous year, indicating a worsening operational performance[50] Cash Flow - Net cash flow from operating activities was a negative CNY 29,219,215.98, down 320.56% from a positive CNY 15,211,693.01 in the same period last year[9] - The cash flow from operating activities was ¥356,239,837.53, down from ¥391,328,440.17, reflecting a decrease of about 9.0%[57] - The net cash flow from operating activities was -29,219,215.98 CNY, compared to 13,247,526.54 CNY in the previous period, indicating a significant decline[58] - The net cash flow from investment activities was -11,698,259.70 CNY, compared to 22,529,403.69 CNY in the previous period, showing a significant decline[62] - The company reported a net increase in cash and cash equivalents of -14,960,165.71 CNY, compared to -11,498,118.33 CNY in the previous period, indicating a worsening cash position[59] Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,606,974,611.25, a decrease of 1.07% from CNY 3,645,939,804 at the end of the previous year[9] - Current liabilities decreased to CNY 815,032,434.34 from CNY 909,661,158.25, indicating a reduction of about 10.4%[42] - The total liabilities stood at CNY 1,242,428,805.86, a decrease from CNY 1,256,225,878.85, reflecting a decline of approximately 1.1%[42] - The equity attributable to shareholders decreased to CNY 2,315,159,728.37 from CNY 2,340,360,125.72, a decline of about 1.1%[43] - The company’s total non-current liabilities increased to CNY 427,396,371.52 from CNY 346,564,720.60, indicating a growth of about 23.3%[42] Expenses - Total operating costs increased to ¥365,980,206.32 from ¥318,054,324.43, representing a growth of approximately 15.1% year-over-year[49] - Research and development expenses rose to ¥6,091,352.39, up from ¥4,029,596.06, marking a significant increase of about 51.2%[49] - The company reported a significant increase in sales expenses, which rose to ¥90,266,812.17 from ¥66,139,703.49, an increase of about 36.4%[49] - Other income decreased to ¥8,054,026.46 from ¥19,028,747.87, a decline of approximately 57.7%[49] Shareholder and Corporate Governance - The number of ordinary shareholders at the end of the reporting period was 18,568[13] - The company received a criminal judgment requiring the defendant Liu Qun to repay a total of RMB 91.824926 million for funds misappropriated from the company, with additional responsibilities assigned to other defendants[18] - Liu Qun has repaid a total of RMB 121.474926 million, including RMB 3.6 million already returned, to resolve the issue of misappropriated funds[19] - The company’s stock has been under risk warning since June 5, 2019, due to the misappropriation of funds by the controlling shareholder[20] - The controlling shareholder Liu Qun has increased his shareholding by 1,628,800 shares, amounting to RMB 9.3032522 million, but still has an outstanding commitment to increase by 1,551,200 shares[25] Investments and Projects - As of March 31, 2021, the company has invested RMB 479.70 million in the oral solid preparation GMP technology transformation project, achieving an investment progress of 83.75%[29] - The Tian Sheng (Chongqing) Modern Pharmaceutical Logistics Headquarters Base project has seen a cumulative investment of RMB 138.81 million, also with an investment progress of 83.75% as of March 31, 2021[29] - The company raised a total of RMB 1,185.61 million by issuing 53 million shares at a price of RMB 22.37 per share, with a net amount of RMB 1,078.79 million after deducting issuance costs[29] - The company utilized RMB 65 million of idle raised funds to temporarily supplement working capital during the reporting period[29] - The company has engaged in wealth management with idle raised funds amounting to RMB 40 million, with no overdue amounts reported[31]